Boehringer Ingelheim: Board Change
13.11.2012 - Allan Hillgrove will take over Engelbert Tjeenk Willink's responsibilities on the firms board and as its Managing Director of Division Marketing and Sales Prescription as of 1 January 2013.
Willink, Member of the Board of Managing Directors at Boehringer Ingelheim GmbH and responsible for Marketing and Sales of Prescription Medicines since 2009, has decided to leave the pharma major and global contract manufacturer at the end of 2012. The native Australian (52), who joined the Boehringer Group in 1982, became Head of Established Markets in 2010. Willink worked as Head of Marketing for Prescription Medicines at Boehringer from 2001-2005. Before that he acted as Head of Marketing and Sales in Canada, and from 2005-2008 he worked as Country Manager of Boehringer Ingelheim Mexico. Last year, the pharma giant achieved net sales of over 13bn. R&D expenditure in the business area Prescription Medicines, the marketing area that will now be led by Hillgrove, corresponded to 23.5% of the company’s net sales.http://www.european-biotechnology-news.com/people/bio-people/2012-2/allan-hillgrove.html